Immix Biopharma Inc

NASDAQ IMMX

Data sourced from iex and EODHD
Download Data

Immix Biopharma Inc Cash Flow Statement 2020 - 2024

This table shows the Cash Flow Statement for Immix Biopharma Inc going from 2020 until 2024. The cash flow statement is a financial statement that shows the inflow and outflow of cash and cash equivalents from a company's operating, investing, and financing activities over a specified period. It provides crucial information about a company's ability to generate and manage cash, which is essential for its day-to-day operations, investments, and debt obligations.
Cash Flow Statement Trend Unit 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30
Net Income
M -5 -5 -4 -4 -2 -4 -2 -2 -1 -23 0 0 -1 -1 0
Depreciation and Amortization
M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Non-Cash Items (Other)
M 0 1 1 -1 0 295 0 0 - 0 0 0 0 1 -
Operating Cash Flow
M -4 -3 -3 -4 -2 -4 -1 -1 -1 -1 0 0 0 0 0
Capital Expenditures
M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Net Acquisitions
M - - - - - - - - - - - - - - -
Other Investing Activities
M - - - - - - - - - - - - - - -
Investing Cash Flow
M - - - - - - - - - - - - - - -
Repayment/Issuance of Debt (Net)
M - - - - - - - 0 0 0 0 0 0 - 0
Equity Repurchase (Common, Net)
M - 0 0 - - 0 0 0 - - - - - - -
Dividends Paid
M - - - - - - - - - - - - - - -
Other Financial Activities
M 16 0 0 0 0 -2,910 -3 0 - 0 0 0 0 - 0
Financing Cash Flow
M 16 0 0 0 0 -2,910 -3 0 - 0 0 0 0 - 0
Exchange Rate Adjustment
M - - - - - - - - - - - - - - -
Beginning Cash
M 18 20 13 11 13 17 18 19 18 0 0 0 0 0 0
Ending Cash
M 29 18 20 13 11 13 17 18 19 18 0 0 0 0 0
Stock-Based Compensation
M 1 1 1 0 0 0 0 0 0 0 0 0 0 - -
Issuance/Purchase of Shares
M - 0 0 - - 0 0 0 - - - - - - -
Capital Stock Change
M 16 1 10 5 0 0 0 0 3 - - - - - -
Working Capital
M 27 16 20 13 12 14 17 18 20 18 -6 -6 -6 -5 -
Free Cash Flow
M -4 -3 -3 -4 -2 -4 -1 -1 -1 -1 0 0 0 0 0

StockViz Staff

September 19, 2024

Any question? Send us an email